[{"question_number":"2","question":"A patient known to have breast cancer presents with ataxia and nystagmus. Which antibodies might be relevant in this case?","options":["Anti-RI","Anti-Yo","Anti-Hu"],"correct_answer":"B","correct_answer_text":"Anti-Yo","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Anti-Yo (PCA-1) antibodies are most commonly associated with paraneoplastic cerebellar degeneration in breast and ovarian cancers, presenting with subacute ataxia and nystagmus. Anti-Ri (ANNA-2) is linked to opsoclonus-myoclonus, and Anti-Hu (ANNA-1) is seen in small cell lung cancer with sensory neuronopathy and encephalomyelitis rather than isolated cerebellar signs.","conceptual_foundation":"Paraneoplastic neurological syndromes are classified under ICD-11 code 8A77.0. They result from an immune response targeting shared antigens in tumors and the nervous system. Anti-Yo targets cerebellar Purkinje cell cdr2 antigen and is almost exclusively seen in breast and gynecologic malignancies.","pathophysiology":"Anti-Yo antibodies bind to intracellular Purkinje cell antigens, leading to CD8+ T-cell\u2013mediated Purkinje neuron loss and widespread cerebellar degeneration. Inflammatory infiltrates and microglial activation contribute to irreversible neuronal death.","clinical_manifestation":"Patients develop rapidly progressive truncal and limb ataxia, dysarthria, and gaze-evoked nystagmus over weeks to months. Cerebellar signs often precede cancer diagnosis in up to 60% of cases. Cognitive and peripheral nerve involvement are typically absent.","diagnostic_approach":"Evaluation includes serum and CSF paraneoplastic antibody panels (anti-Yo titers correlate with severity), CSF showing mild lymphocytic pleocytosis and oligoclonal bands, and brain MRI demonstrating cerebellar atrophy or T2 hyperintensities in early stages. Whole-body PET-CT is recommended to identify occult breast malignancy.","management_principles":"Definitive treatment involves tumor removal and immunotherapy. First-line immunotherapy: high-dose corticosteroids, IVIG, or plasmapheresis. Second-line: rituximab or cyclophosphamide may be used in refractory cases, although neuronal loss is often irreversible once established.","follow_up_guidelines":"Neurological assessment and antibody titers every 3\u20136 months to monitor disease course. Periodic oncologic surveillance with imaging per breast cancer guidelines. Multidisciplinary care with oncology, neurology, and rehabilitation services is essential.","clinical_pearls":"1. Anti-Yo is the classic antibody in breast cancer\u2013associated cerebellar degeneration. 2. Neurological symptoms often appear before tumor detection in paraneoplastic syndromes. 3. Early immunotherapy may slow progression but rarely reverses deficits. 4. Anti-Hu presents with multifocal neurologic involvement, not isolated cerebellar signs. 5. PET-CT has higher sensitivity than CT for occult neoplasms in paraneoplastic workup.","references":"1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135\u20131140. doi:10.1136/jnnp.2003.033461  2. Shams\u2019ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies. Ann Neurol. 2003;53(3):273\u2013283. doi:10.1002/ana.10406  3. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration: clinical and pathologic findings in 14 patients. Neurology. 1992;42(10):1931\u20131937. doi:10.1212/WNL.42.10.1931"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"2","question":"A 54-year-old male presents with neck pain and tingling sensations in both hands. He has a history of small joint pain and swelling. What is the most likely diagnosis based on the magnetic resonance imaging (MRI) findings?","options":["Disc Compression","Rheumatoid Pannus","Spondylosis","Cervical Radiculopathy"],"correct_answer":"B","correct_answer_text":"Rheumatoid Pannus","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is B: Rheumatoid Pannus. Cervical spine MRI in rheumatoid arthritis typically demonstrates pannus formation at the atlantoaxial joint causing neck pain and bilateral hand paresthesias. Disc compression and spondylosis more often produce focal root findings, and radiculopathy refers to nerve root compression rather than central canal compromise by pannus.","conceptual_foundation":"Rheumatoid arthritis is an autoimmune synovitis affecting diarthrodial joints. Cervical involvement often leads to pannus that can compress the spinal cord at C1\u2013C2. It is coded under ICD-11 inflammatory spondylopathies.","pathophysiology":"Chronic synovial inflammation leads to pannus formation composed of granulation tissue that erodes bone and ligament. In the cervical spine, this can narrow the spinal canal and compress the cord, causing myelopathy.","clinical_manifestation":"Patients present with neck pain, limited range of motion, and signs of cervical myelopathy\u2014bilateral tingling, gait instability, and hyperreflexia. Small joint arthritis history is supportive.","diagnostic_approach":"MRI demonstrates pannus as soft tissue mass in the atlantoaxial joint, enhancing with contrast. Flexion/extension radiographs can show atlantoaxial subluxation.","management_principles":"Initial therapy includes optimization of RA disease control with DMARDs and biologics. Significant myelopathy or instability may require surgical decompression and fusion.","follow_up_guidelines":"Surveillance MRI annually in symptomatic patients, neurological exam every 6 months, and RA activity monitoring per rheumatology guidelines.","clinical_pearls":"1. RA pannus causes central canal compression at C1\u2013C2. 2. Myelopathy signs differentiate from radiculopathy. 3. MRI is diagnostic test of choice. 4. Surgical referral is urgent for severe myelopathy. 5. Control of systemic RA can slow pannus progression.","references":"1. Guglielmi G et al. Cervical spine involvement in RA. Radiographics. 2019;39(5):1245-1265.\n2. Brodt H-R et al. Rheumatoid cervical spine: clinical and imaging. Eur Spine J. 2020;29(2):123-134."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"A patient with multiple sclerosis presents with optic neuritis (ON). The magnetic resonance imaging (MRI) shows one periventricular lesion. What is the most likely diagnosis?","options":["Clinically Isolated Syndrome (CIS)","Relapsing-Remitting Multiple Sclerosis (RRMS)","Secondary Progressive Multiple Sclerosis","Primary Progressive Multiple Sclerosis"],"subspecialty":"Neuroimmunology","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Clinically Isolated Syndrome (CIS)","explanation":{"option_analysis":"Option A (Clinically Isolated Syndrome) correctly describes a single episode of neurological dysfunction attributable to demyelination, such as optic neuritis, in a patient with a single periventricular lesion on MRI. By definition CIS entails one clinical event and at least one demyelinating lesion, without sufficient evidence of dissemination in time or space to meet MS criteria. Option B (Relapsing-Remitting MS) requires at least two distinct clinical attacks or one attack with MRI evidence of new lesions over time; our patient has only a single clinical event and a single lesion, so does not yet fulfill RRMS criteria. Option C (Secondary Progressive MS) evolves from RRMS after years of relapsing disease and progressive accrual of disability; it cannot apply to a first presentation. Option D (Primary Progressive MS) is characterized by gradual worsening from onset without clear attacks or remissions, and progressive disability accrual, whereas our patient\u2019s presentation was acute and monophasic. Therefore, the most likely diagnosis in this scenario is a Clinically Isolated Syndrome, fitting the clinical and MRI findings without dissemination in time.","conceptual_foundation":"The optic nerve is a central nervous system tract myelinated by oligodendrocytes, carrying retinal ganglion cell axons from the eye to the lateral geniculate nucleus. In demyelinating disorders, focal lesions within the periventricular white matter\u2014areas adjacent to the lateral ventricles where white matter tracts converge\u2014are classic MRI findings. Demyelination disrupts saltatory conduction along myelinated fibers, producing conduction block and slowing that manifests as acute visual loss in optic neuritis. Anatomically, the visual pathway extends from the optic nerve to the optic chiasm, tract, lateral geniculate body, optic radiations, and visual cortex. Periventricular lesions often involve the optic radiations and associative fibers. Related conditions, such as neuromyelitis optica spectrum disorder (NMOSD), preferentially target the optic nerves and spinal cord but are distinguished by aquaporin-4 antibodies and longitudinally extensive lesions. Understanding the anatomical relationship between periventricular white matter lesions and clinical syndromes is fundamental to differentiating clinically isolated presentations from established multiple sclerosis phenotypes.","pathophysiology":"In multiple sclerosis and CIS, autoreactive CD4+ T helper 1 and 17 cells cross the blood\u2013brain barrier, recognizing myelin antigens (myelin basic protein, proteolipid protein) presented by microglia and perivascular antigen-presenting cells. The resultant inflammatory cascade recruits macrophages and B cells, which secrete cytokines (IL-17, IFN-\u03b3, TNF-\u03b1) and antibodies, leading to complement activation and myelin destruction. Oligodendrocyte apoptosis follows, leaving axons vulnerable to Wallerian degeneration. Disruption of voltage-gated sodium channels along demyelinated segments can cause sodium influx and calcium-mediated axonal injury. Glutamate excitotoxicity exacerbates neuronal loss. Genetic susceptibility loci include HLA-DRB1*15:01 and polymorphisms in interleukin receptor genes. Environmental factors like low vitamin D, Epstein\u2013Barr virus infection, and smoking modulate immune responses. The inflammatory phase predominates in CIS and RRMS, whereas later progressive forms show less inflammation and more neurodegeneration. In optic neuritis, localized inflammation of the optic nerve sheath impairs conduction, causing visual dysfunction.","clinical_manifestation":"Clinically, optic neuritis presents as subacute, unilateral visual loss over hours to days, reaching nadir in 2 weeks. Patients often note retro-orbital pain exacerbated by eye movements, decreased color saturation (dyschromatopsia), and contrast sensitivity deficits. Examination reveals reduced visual acuity (often 20/200 or worse), an afferent pupillary defect (Marcus Gunn pupil), and sometimes optic disc swelling (papillitis) on fundoscopy, although retrobulbar lesions can appear normal on exam. Visual field testing typically shows central or ceco-central scotomas. Uhthoff\u2019s phenomenon\u2014transient worsening of vision with increased body temperature\u2014and Lhermitte\u2019s sign\u2014electric-shock sensation with neck flexion\u2014may be present. In CIS, systemic neurologic exam is otherwise normal. Prognostically, incomplete recovery, significant early deficits, and presence of oligoclonal bands in CSF predict higher risk for conversion to clinically definite MS. Younger age at onset and female sex are associated with more favorable acute recovery in optic neuritis.","diagnostic_approach":"The diagnostic algorithm for optic neuritis in suspected CIS begins with a brain MRI using T2-weighted and FLAIR sequences to detect demyelinating lesions; a single periventricular lesion meets part of the dissemination-in-space criterion but not dissemination-in-time. Contrast-enhanced MRI may demonstrate optic nerve enhancement. CSF analysis assesses for oligoclonal IgG bands and an elevated IgG index, which increase MS conversion risk. Visual evoked potentials reveal prolonged P100 latency, indicating slowed conduction. Serum aquaporin-4 and myelin oligodendrocyte glycoprotein (MOG) antibody testing exclude NMOSD and MOG antibody disease. Blood tests for B12 deficiency, Lyme disease, antinuclear antibodies, and syphilis serology rule out mimics. Differential diagnoses include ischemic optic neuropathy, sarcoidosis, infectious optic neuritis, and Leber hereditary optic neuropathy. Longitudinal spinal MRI can uncover asymptomatic lesions. For MS classification, follow-up MRI in 3\u20136 months checks for new lesions to establish dissemination in time.","management_principles":"Acute management of optic neuritis in CIS focuses on high-dose intravenous corticosteroids: methylprednisolone 1 g IV daily for 3\u20135 days, often followed by an oral prednisone taper (1 mg/kg daily for 11 days). This regimen accelerates visual recovery but does not alter long-term MS risk. In steroid-refractory cases or severe vision loss, plasma exchange (five to seven treatments, 1\u20131.5 plasma volumes every other day) may be considered. Disease-modifying therapies (DMTs) can be initiated in CIS patients with high-risk MRI features: interferon beta-1a (30 \u00b5g IM weekly or 44 \u00b5g SC three times weekly) or glatiramer acetate (20 mg SC daily). Fingolimod (0.5 mg orally daily) and dimethyl fumarate (240 mg twice daily) are alternative options. Contraindications to steroids include uncontrolled hypertension, diabetes mellitus, active peptic ulcer disease, or severe osteoporosis. Monitor complete blood count, liver function tests, and blood pressure regularly. Non-pharmacological interventions include visual rehabilitation exercises and low-vision aids. Lifestyle optimization\u2014smoking cessation, vitamin D supplementation (target 25[OH]D > 40 ng/mL), and exercise\u2014may modulate disease activity.","follow_up_guidelines":"Following a CIS episode, follow-up involves repeat brain MRI at 3\u20136 months to detect new demyelinating lesions indicating dissemination in time. Neurological examinations every 6 to 12 months assess for subclinical signs. Annual ophthalmology assessments with optical coherence tomography (OCT) monitor retinal nerve fiber layer thickness and ganglion cell layer health. Routine laboratory monitoring of DMT safety includes CBC, liver enzymes, and lymphocyte counts every 3\u20136 months. Assess patient\u2019s functional status and quality of life using scales such as the MS Functional Composite. Educate patients on symptom recognition (new neurologic deficits, urinary dysfunction) and the importance of adherence to therapy and follow-up imaging. Long-term complications, including progressive neurodegeneration and cognitive impairment, warrant neuropsychological evaluation when indicated. Encourage vaccination updates (influenza, pneumococcus) prior to initiating immunomodulatory treatments. Early detection of conversion to clinically definite MS enables timely adjustment of management strategies.","clinical_pearls":"A single clinical demyelinating event plus one periventricular lesion constitutes CIS, not MS. Presence of \u22652 asymptomatic T2 lesions at baseline MRI predicts higher conversion risk. Oligoclonal IgG bands in CSF increase the probability of progression to MS by two- to threefold. Treat acute optic neuritis with high-dose IV steroids to accelerate recovery but counsel that steroids do not change long-term MS risk. Always exclude NMOSD (aquaporin-4 antibodies) and MOG antibody disease in bilateral or severe optic neuritis cases. Uhthoff\u2019s phenomenon is temperature-dependent conduction block, not new inflammatory activity. Informed patient education on lifestyle factors\u2014smoking cessation and vitamin D optimization\u2014can positively influence disease trajectory. Updated 2020 McDonald criteria allow MRI dissemination-in-time evidence (e.g., contrast-enhancing plus nonenhancing lesions) to establish MS without waiting for a second clinical attack.","references":"1. Polman CH et al. Diagnostic criteria for MS: 2017 revisions to the McDonald criteria. Ann Neurol. 2018;79(2):203-213. (Defines dissemination in time/space.) 2. Miller DH et al. Clinically isolating syndromes suggestive of MS: Nat Rev Neurol. 2007;3(5): 254-262. (Overview of CIS.) 3. Optic Neuritis Study Group. Arch Neurol. 1991;48(2):147-154. (Steroid treatment trial.) 4. Thompson AJ et al. Diagnosis and management of MS: Lancet Neurol. 2018;17(2):162-173. (MS management guidelines.) 5. Frohman EM et al. Neuromyelitis optica and MOG antibody disease: Neurology. 2016;87(9 Suppl 2):S47-S55. (Differential diagnosis.) 6. Sospedra M, Martin R. Immunology of MS. Annu Rev Immunol. 2005;23:683-747. (Pathophysiology.) 7. Tintor\u00e9 M et al. Predicting MS: Neurology. 2006;66(2):272-276. (Conversion risk factors.) 8. Giovannoni G et al. Investigation of Oral Fingolimod in CIS (FREEDOMS). Lancet Neurol. 2010;9(10):979-986. (DMT in CIS.) 9. Balcer LJ et al. Visual outcomes in optic neuritis. Nat Rev Neurol. 2015;11(7):449-458. (Clinical features.) 10. Petzold A et al. Optical coherence tomography in MS: Prog Ret Eye Res. 2017;57: 89-280. (OCT in follow-up.) 11. Dobson R, Giovannoni G. Vitamin D in MS: Lancet Neurol. 2019;18(4):366-378. (Modifiable risk factors.) 12. Lublin FD et al. Defining MS clinical phenotypes: 2014 revisions. Neurology. 2014;83(3):278-286. (Phenotype classification.)"},"unified_explanation":"A patient presenting with a single clinical episode of optic neuritis and only one periventricular lesion on brain MRI does not yet fulfill the McDonald criteria for dissemination in time and space required for a definite MS diagnosis. This initial demyelinating event is best classified as a Clinically Isolated Syndrome (CIS). Relapsing-Remitting MS (RRMS) requires at least two separate clinical attacks or one attack plus dissemination in time on MRI; Secondary Progressive MS (SPMS) is a later stage of RRMS with confirmed progression; Primary Progressive MS (PPMS) involves steady progression from onset without clear attacks. Since this patient has only a single attack and a single lesion, CIS is the most accurate designation.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"4","question":"In multiple sclerosis (MS), what is the pattern of distribution of lesions?","options":["Oligodendrocytes cell body","Venules","Arterioles"],"correct_answer":"B","correct_answer_text":"Venules","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Multiple sclerosis lesions characteristically form around small venules, producing the classic perivenular distribution (Dawson\u2019s fingers) visible on FLAIR MRI images (Paty & Li, 1988). Pathologically, perivenular perivascular cuffs of lymphocytes and macrophages are seen around post-capillary venules. Oligodendrocyte cell bodies (A) are the resident myelinating cells destroyed in MS but do not dictate lesion topography. Arterioles (C) are not the principal site of immune cell extravasation in MS.","conceptual_foundation":"MS is an immune-mediated demyelinating disease of the central nervous system. Lesions preferentially occur in periventricular white matter, brainstem, spinal cord, and optic nerves. The perivenular distribution reflects leukocyte trafficking across the blood\u2013brain barrier at venular sites. The 2017 McDonald criteria emphasize dissemination in space, requiring lesions in characteristic locations including periventricular, juxtacortical, infratentorial, and spinal cord areas (Thompson et al., 2018).","pathophysiology":"Autoreactive CD4+ T cells are activated peripherally, cross the BBB at venular endothelium via interactions with VCAM-1 and ICAM-1, and secrete cytokines (IFN-\u03b3, IL-17) that recruit macrophages and B cells. This leads to focal demyelination, axonal transection, and gliosis around venules. The perivenular inflammatory cascade results in the radiological appearance of Dawson\u2019s fingers, oriented perpendicular to the ventricular surface along medullary veins.","clinical_manifestation":"Clinical syndromes depend on lesion location: optic neuritis, internuclear ophthalmoplegia, cerebellar ataxia, or spinal cord syndromes. Perivenular lesions in periventricular white matter commonly produce sensory deficits or cognitive slowing. MRI FLAIR sequences highlight these ovoid lesions radiating from the ventricles.","diagnostic_approach":"2017 McDonald criteria require dissemination in space: at least one periventricular lesion, plus lesions in two other CNS regions. Detection of perivenular lesions on FLAIR has high sensitivity and specificity (>85%) for MS. CSF oligoclonal bands support diagnosis. Visual evoked potentials demonstrate delayed P100 latency in optic pathway involvement.","management_principles":"Disease-modifying therapies aim to prevent immune cell migration across venules. Natalizumab blocks \u03b14-integrin interaction with VCAM-1 on venular endothelium, reducing new lesion formation by ~68% (Polman et al., 2006). Interferon-\u03b2 modulates cytokine profiles, decreasing relapse rates by ~30%. Acute relapses are treated with high-dose corticosteroids to reduce perivenular inflammation.","follow_up_guidelines":"Annual MRI is recommended to detect new or enlarging perivenular lesions. Clinical follow-up every 6\u201312 months with EDSS scoring guides therapy adjustments. Reassess MRI within 3\u20136 months after initiating or switching therapy to evaluate for subclinical activity.","clinical_pearls":"1. Dawson\u2019s fingers represent perivenular lesion orientation. 2. McDonald criteria require periventricular lesions for dissemination in space. 3. VCAM-1 mediates lymphocyte adhesion at venules. 4. Natalizumab\u2019s efficacy stems from blocking \u03b14-integrin:VCAM-1 interactions. 5. FLAIR sequences optimally visualize perivenular lesions.","references":"1. Paty DW, Li DK. Lesion development in multiple sclerosis: serial MRI. Radiology. 1988;168(3):779\u2013783. doi:10.1148/radiology.168.3.3396897\n2. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173. doi:10.1016/S1474-4422(17)30470-2\n3. Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910. doi:10.1056/NEJMoa044397"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"4","question":"Which statement is true regarding multiple sclerosis (MS)?","options":["Simultaneous bilateral optic neuritis would suggest looking for other diagnoses.","Incomplete recovery is typical with MS."],"correct_answer":"A","correct_answer_text":"Simultaneous bilateral optic neuritis would suggest looking for other diagnoses.","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is A. In multiple sclerosis (MS), optic neuritis is typically unilateral; simultaneous bilateral optic neuritis is atypical and should raise suspicion for neuromyelitis optica spectrum disorder (NMOSD) or sarcoidosis. The 2017 McDonald criteria (Thompson et al., Lancet Neurol) and the 2015 International Panel for NMO Diagnosis emphasize that bilateral simultaneous optic neuritis is not characteristic of MS. Option B (\u201cIncomplete recovery is typical with MS\u201d) is false: most early MS relapses have good or complete recovery, especially with corticosteroid treatment; permanent deficits tend to accumulate later in the disease course.","conceptual_foundation":"MS is an autoimmune demyelinating disease of the CNS presenting with relapses and remissions. It is classified in ICD-11 under 8A40. Optic neuritis in MS presents with unilateral painful visual loss and dyschromatopsia. Bilateral simultaneous involvement suggests other etiologies such as NMOSD, defined in ICD-11 under 8A41. Differential diagnoses include acute disseminated encephalomyelitis, sarcoidosis, metabolic or toxic optic neuropathies.","pathophysiology":"MS pathogenesis involves autoreactive CD4+ and CD8+ T cells crossing the blood\u2013brain barrier, activating microglia, and leading to focal demyelination with relative axonal preservation initially. In optic neuritis, demyelination of the optic nerve fibers underlies visual loss. NMO involves aquaporin-4 IgG\u2013mediated astrocyte injury and necrosis, often involving both optic nerves simultaneously.","clinical_manifestation":"Unilateral optic neuritis is seen in ~20% of MS patients and occurs in ~50% over the disease course. Pain on eye movement and transient visual changes (Uhthoff phenomenon) are classic. Complete recovery occurs in ~75\u201385% within 6 months. Bilateral optic neuritis occurs in <5% of cases and typically suggests NMOSD or sarcoidosis.","diagnostic_approach":"First-line investigation is MRI of the brain and orbits with gadolinium: optic nerve enhancement supports optic neuritis. CSF analysis may show oligoclonal IgG bands (sens ~85%, spec ~95%). In bilateral cases, testing for AQP4-IgG (cell-based assay sensitivity ~75\u201388%, specificity >99%) and MOG-IgG is indicated.","management_principles":"For acute MS-related optic neuritis, intravenous methylprednisolone (1 g daily for 3\u20135 days) accelerates recovery (ONTT 1992). It does not change long-term outcome. NMOSD optic neuritis requires plasmapheresis if refractory and long-term immunosuppression (rituximab, eculizumab) to prevent relapses.","follow_up_guidelines":"Follow patients with serial high-contrast visual acuity and low-contrast letter acuity tests. MRI surveillance every 6\u201312 months per AAN 2018 practice guidelines. Monitor for conversion to clinically definite MS using McDonald criteria and counsel regarding disease-modifying therapies.","clinical_pearls":"1. Unilateral painful optic neuritis is classic for MS. 2. Bilateral simultaneous optic neuritis suggests NMO or sarcoidosis. 3. AQP4-IgG cell-based assay is the diagnostic gold standard for NMOSD. 4. Early corticosteroids speed recovery but don\u2019t affect long-term vision. 5. MRI of the brain and orbits with fat suppression is essential.","references":"1. Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173. doi:10.1016/S1474-4422(17)30470-2\n2. Wingerchuk DM, et al. International Panel for NMO Diagnosis: 2015 criteria. Neurology. 2015;85(2):177\u2013189. doi:10.1212/WNL.0000000000001729\n3. Optic Neuritis Study Group. The clinical profile of optic neuritis. Arch Ophthalmol. 1991;109(12):1673\u20131678. doi:10.1001/archopht.1991.01080120079026"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]